10511-1-AP

antibody from Proteintech Group

Targeting: UCK2 UMPK

Provider product page for 10511-1-AP

Western blot

ELISA

Immunoprecipitation

Antibody data

Antibody Data
Antigen structure
References [23]
Comments [0]
Validations
Western blot [1]

Submit

Product number: 10511-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#10511-1-AP, RRID:AB_2241182
Product name: UCK2 antibody
Antibody type: Polyclonal
Description: KD/KO validated UCK2 antibody (Cat. #10511-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IP, WB, ELISA.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

UCK2 protein structure - 10511-1-AP shown in red.

Submitted references Predicting neuroblastoma prognosis using machine learning analysis of metabolism-related gene network perturbation.

Liu X, Hu X, Cai Q, Yuan C, Wang J
BMC pediatrics 2026 Jan 26;26(1):126

Uridine-cytidine kinase 2 is correlated with immune, DNA damage repair and promotion of cancer stemness in pan-cancer.

Tian J, Li Y, Tong Y, Zhang Y, Zhao T, Kang Y, Bi Q
Frontiers in oncology 2025;15:1503300

Uridine-cytidine kinase 2 as a novel potential prognostic and therapeutic biomarker in gastric cancer.

Sun W, Guo H, Cai M, Ma G, Zhang L, Yu Y, Zhan H
Translational cancer research 2025 Nov 30;14(11):8070-8085

The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation.

Sha N, Zhou B, Hou G, Xi Z, Wang W, Yan M, He J, Zhou Y, Xia Q, Jiang Y, Zhao Q
Oncogene 2025 May;44(16):1078-1092

mTORC1 regulates the pyrimidine salvage pathway by controlling UCK2 turnover via the CTLH-WDR26 E3 ligase.

Pham BQ, Yi SA, Ordureau A, An H
Cell reports 2025 Jan 28;44(1):115179

Uridine-Cytidine Kinase 2 (UCK2)/Uridine-Cytidine Kinase Like 1 (UCKL1) complex exacerbates the differentiation of myocardial fibroblasts via TRIM21/Smurf2/Smad3 pathway after myocardial infarction.

Zhou X, Zhang Y, Wang H, Qi Z, Gu Z, Cui J, Hu Z, Wang Y
Molecular biomedicine 2025 Dec 29;6(1):151

PAX3-FOXO1 Drives Targetable Cell State-Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma.

Paras KI, Brunner JS, Montero AM, Boyer JA, Jackson BT, Chakraborty S, Xie A, Guillan K, Siddiquee A, Pajuelo Torres L, Rabinowitz JD, Kung AL, You D, Dela Cruz FS, Finley LWS
Cancer research 2025 Dec 1;85(23):4718-4733

p53 activation enhances the sensitivity of non-small cell lung cancer to the combination of SH003 and docetaxel by inhibiting de novo pyrimidine synthesis.

Choi YJ, Lee K, Lee SY, Kwon Y, Woo J, Jeon CY, Ko SG
Cancer cell international 2024 May 4;24(1):156

Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

Watanabe T, Yamamoto Y, Kurahashi Y, Kawasoe K, Kidoguchi K, Ureshino H, Kamachi K, Yoshida-Sakai N, Fukuda-Kurahashi Y, Nakamura H, Okada S, Sueoka E, Kimura S
Blood advances 2024 Mar 26;8(6):1345-1358

Immune- and metabolism-related gene signature analysis uncovers the prognostic and immune microenvironments of hepatocellular carcinoma.

Gu Y, Ma E, Jiang S, Shan Z, Xia G, Ma R, Fu J, Wang Z
Journal of cancer research and clinical oncology 2024 Jun 19;150(6):311

Glucose limitation protects cancer cells from apoptosis induced by pyrimidine restriction and replication inhibition.

Nam M, Xia W, Mir AH, Jerrett A, Spinelli JB, Huang TT, Possemato R
Nature metabolism 2024 Dec;6(12):2338-2353

A prognostic and immune related risk model based on zinc homeostasis in hepatocellular carcinoma.

Shi Y, Ye R, Gao Y, Xia F, Yu XF
iScience 2024 Apr 19;27(4):109389

Salvage of ribose from uridine or RNA supports glycolysis in nutrient-limited conditions.

Skinner OS, Blanco-Fernández J, Goodman RP, Kawakami A, Shen H, Kemény LV, Joesch-Cohen L, Rees MG, Roth JA, Fisher DE, Mootha VK, Jourdain AA
Nature metabolism 2023 May;5(5):765-776

Oncogene-like addiction to aneuploidy in human cancers.

Girish V, Lakhani AA, Scaduto CM, Thompson SL, Brown LM, Hagenson RA, Sausville EL, Mendelson BE, Lukow DA, Yuan ML, Kandikuppa PK, Stevens EC, Lee SN, Salovska B, Li W, Smith JC, Taylor AM, Martienssen RA, Liu Y, Sun R, Sheltzer JM
bioRxiv : the preprint server for biology 2023 Jan 10;

Uridine-cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine.

Xu Z, Flensburg C, Bilardi RA, Majewski IJ
Nucleic acids research 2023 Dec 11;51(22):12031-12042

Oncogene-like addiction to aneuploidy in human cancers.

Girish V, Lakhani AA, Thompson SL, Scaduto CM, Brown LM, Hagenson RA, Sausville EL, Mendelson BE, Kandikuppa PK, Lukow DA, Yuan ML, Stevens EC, Lee SN, Schukken KM, Akalu SM, Vasudevan A, Zou C, Salovska B, Li W, Smith JC, Taylor AM, Martienssen RA, Liu Y, Sun R, Sheltzer JM
Science (New York, N.Y.) 2023 Aug 25;381(6660):eadg4521

A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma.

Pal S, Kaplan JP, Nguyen H, Stopka SA, Savani MR, Regan MS, Nguyen QD, Jones KL, Moreau LA, Peng J, Dipiazza MG, Perciaccante AJ, Zhu X, Hunsel BR, Liu KX, Alexandrescu S, Drissi R, Filbin MG, McBrayer SK, Agar NYR, Chowdhury D, Haas-Kogan DA
Cancer cell 2022 Sep 12;40(9):957-972.e10

A reversible metabolic stress-sensitive regulation of CRMP2A orchestrates EMT/stemness and increases metastatic potential in cancer.

Boukouris AE, Zhang Y, Saleme B, Kinnaird A, Zhao YY, Liu Y, Zervopoulos SD, Das SK, Mittal RD, Haromy A, Lorenzana-Carrillo MA, Krysler AR, Cromwell CR, Hubbard BP, Sutendra G, Michelakis ED
Cell reports 2022 Mar 15;38(11):110511

Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.

Yoshida-Sakai N, Watanabe T, Yamamoto Y, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Kimura S
International journal of cancer 2022 Apr 1;150(7):1184-1197

Prognostic and predictive role of a metabolic rate-limiting enzyme signature in hepatocellular carcinoma.

Wang Z, Fu Y, Xia A, Chen C, Qu J, Xu G, Zou X, Wang Q, Wang S
Cell proliferation 2021 Oct;54(10):e13117

Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway.

Zhou Q, Jiang H, Zhang J, Yu W, Zhou Z, Huang P, Wang J, Xiao Z
Cancer management and research 2018;10:6339-6355

Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines.

Murase M, Iwamura H, Komatsu K, Saito M, Maekawa T, Nakamura T, Yokokawa T, Shimada Y
Pharmacology research & perspectives 2016 Feb;4(1):e00206

Mechanisms of resistance to azacitidine in human leukemia cell lines.

Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K, Muroi K, Ozawa K
Experimental hematology 2014 Apr;42(4):294-306.e2

No comments: Submit comment

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: The UCK2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human UCK2. This antibody recognizes human, mouse, rat antigen. The UCK2 antibody has been validated for the following applications: ELISA, WB analysis.
Appendix: 10511-1-AP.pdf

: Show more